Surgical Ablation News
-
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of ...
-
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. NRTX-1001 is being evaluated in a Phase 1/2 clinical trial in people with drug-resistant mesial temporal lobe epilepsy. The data are being ...
-
NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology. In test ...
-
Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation
Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the initiation of AcQForce PFA-CE, a new clinical study that will evaluate the safety and performance of the company’s focal force sensing Pulsed Field Ablation (PFA) catheter and system in combination with ...
-
Boston Scientific Exercises Option to Acquire Farapulse, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. ...
-
USMI Developing the First Surgical Robot for Cancer Surgery
US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery. The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures. Features of the new Canady Surgical ...
-
FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
FARAPULSE Inc. today announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes ...
-
First Patients Treated with Galaxy Medical’s CENTAURI Pulsed Electric Field Cardiac Ablation System
MENLO PARK, California, October 9, 2020 — Galaxy Medical, (Galaxy), a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that the first patients were successfully treated with the proprietary CENTAURI™ System by Dr. Ante Ani in Split, Croatia as part of the ECLIPSE-AF study. This multicenter trial is designed to assess the ...
-
Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. This PFA system – comprising a sheath, generator and catheters – is intended to ablate ...
-
Zenflow Announces $24 Million Financing Round; Appoints Susan Stimson as President
Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series B financing round. The funding was led by Invus Opportunities and included participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia ...
-
Novel radiometry guided microwave ablation technology set to advance with National Institutes of Health Small Business Innovation Research Award
Flagstaff, Arizona – October 9, 2018 – Symple Surgical Inc. (SSI) announced today that we have received a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase I Grant Award totaling $225,000.00. This award will leverage the ongoing R&D and commercialization initiatives with Duke University to pursue the integration of radiometric thermal feedback ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you